Resources

Merck KGaA spinout iOnctura raises cash for cancer trials

Merck KGaA spinout iOnctura has raised a €15 million ($17 million) series A round to support an early-phase solid tumor trial. The company is gearing up to generate data on PI3Kδ inhibitor IOA-244 in humans while hustling a second candidate through...

read more

Brainlab acquires San Diego-based VisionTree Software

Germany-based digital medical technology company Brainlab has acquired VisionTree Software for an undisclosed amount. Based in San Diego, US, VisionTree Software is associated with the development of cloud-based and patient-centric data collection and health...

read more

Hernia meshes allegedly used without clinical evidence

Hernia repair is one of the world’s most common surgical procedures. A hernia occurs when body organs or fatty tissues protrude out of any wall or opening of the surrounding muscles. The most common site of hernia occurrence is the groin. Hernias are visible as...

read more

Atlas Venture’s 2019 Year in Review

2019 was an exciting and busy year at Atlas Venture. Take a look at our year filled with new joiners, partnerships, financings, R&D progress, and more. View the newsletter. The post Atlas Venture’s 2019 Year in Review appeared first on Atlas Venture.

read more

Kyn to Ikena: The Art and Science of Rebranding

When we started to think about changing our company name, we knew it wasn’t something to take lightly — changing our brand and outward facing image was a big deal!  Several companies rebranded over the last few years and built successful biotech...

read more

Our 2019 Year In Review: Macro, Biotech, and Atlas

It’s that time of year again when we pause to reflect on the state of the industry – and there’s more to focus on in biopharma today than just the drug pricing debate. As I described last year, we host two major events in the 4Q every year:...

read more

Venturing A Perspective On The Drug Pricing Debate

The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades. Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of course by the expected...

read more

Hospitals Can Go Green AND Save Money: Here’s How

This article posted on LinkedIn December 2, 2019 I once read something to the effect of, ‘if your sustainability initiatives are costing your company money, you’re doing it wrong.’ This came to mind after reading “Environmental Sustainability:...

read more

The cost of care is killing Americans.

This article posted on LinkedIn November 18, 2019. Thanks Sarah Gantz, Philadelphia Inquirer for reporting that 13% of Americans “know a friend or family member who died in the past five years because he or she could not afford their medical...

read more

Thinking Boldly: Alkermes Acquires Rodin Therapeutics

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics. Read more. The post Thinking Boldly: Alkermes Acquires Rodin Therapeutics appeared first on Atlas Venture.

read more